Tainan, Taiwan (ots/PRNewswire)
Eli Lilly & Company ("Lilly") and ScinoPharm Taiwan Ltd.
("ScinoPharm") announced today that they have reached an amicable
resolution of all ongoing patent litigations between the companies
relating to ScinoPharm's manufacture and sale of gemcitabine
hydrochloride around the world.
As part of the settlement, Lilly has granted ScinoPharm a royalty
bearing license to manufacture and sell gemcitabine hydrochloride
(API) throughout the world, excluding only countries where the Lilly
compound or method of use patents remain in force and the United
About ScinoPharm Taiwan Ltd.
ScinoPharm Taiwan Ltd. is a leading process R&D and API
manufacturing service provider to the global pharmaceutical industry.
With cGMP production facilities, ScinoPharm offers a wide portfolio
of services ranging from custom synthesis for early phase
pharmaceutical activities to brand companies as well as APIs for the
generic industry. Combining cost-effective resources and productivity
of Asia along with extensive regulatory know-how, ScinoPharm is
uniquely positioned to serve global pharmaceutical R&D and
manufacturing needs at any level and for any company in this sector.
For more information please visit http://www.scinopharm.com
About Eli Lilly & Company
Lilly, a leading innovation-driven corporation, is developing a
growing portfolio of pharmaceutical products by applying the latest
research from its own worldwide laboratories and from collaborations
with eminent scientific organizations. Headquartered in Indianapolis,
Indiana, Lilly provides answers -- through medicines and information
-- for some of the world's most urgent medical needs. Additional
information about Lilly is available at http://www.lilly.com
ScinoPharm Taiwan, Ltd.
ots Originaltext: ScinoPharm Taiwan Ltd.
Im Internet recherchierbar: http://www.presseportal.ch
Jessie Wang of ScinoPharm Taiwan, Ltd., +886-6-505-2888,